Compare III & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | CCCC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | 1500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.8M | 185.1M |
| IPO Year | 2006 | 2020 |
| Metric | III | CCCC |
|---|---|---|
| Price | $4.34 | $2.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.50 | ★ $12.20 |
| AVG Volume (30 Days) | 201.1K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 216.67 | 16.45 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $192,745,000.00 | $35,947,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | ★ 4.51 | 1.02 |
| 52 Week Low | $3.57 | $1.21 |
| 52 Week High | $6.45 | $3.82 |
| Indicator | III | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 56.63 |
| Support Level | $4.12 | $2.30 |
| Resistance Level | $5.14 | $3.82 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 92.87 | 79.13 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.